A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer.

导出 OA

翻译打印收藏纠错

作者： Panagiotis A,Konstantinopoulos ^[1] ; Alexandre André B A,da Costa ^[2] ; Doga,Gulhan ^[3] ; Elizabeth K,Lee ^[4] ; Su-Chun,Cheng ^[4] ; Andrea E Wahner,Hendrickson ^[5] ; Bose,Kochupurakkal ^[6] ; David L,Kolin ^[7] ; Elise C,Kohn ^[8] ; Joyce F,Liu ^[9] ; Elizabeth H,Stover ^[4] ; Jennifer,Curtis ^[4] ; Nabihah,Tayob ^[4] ; Madeline,Polak ^[4] ; Dipanjan,Chowdhury ^[4] ; Ursula A,Matulonis ^[6] ; Anniina,Färkkilä ^[4] ; Alan D,D'Andrea ^[10] ; Geoffrey I,Shapiro ^[6]

作者单位： Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA. Panagiotis_konstantinopoulos@dfci.harvard.edu. ^[1] Department of Medical Oncology, AC Camargo Cancer Center, São Paulo, SP, Brazil. ^[2] Department of Biomedical Informatics and Ludwig Center at Harvard, Harvard Medical School, Boston, MA, USA. ^[3] Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA. ^[4] Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA. ^[5] Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA. ^[6] Center for DNA Damage and Repair, Dana-Farber Cancer Institute, Boston, MA, 02215, USA. ^[7] Department of Pathology, Brigham and Women's Hospital, Boston, MA, 02115, USA. ^[8] Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, USA. ^[9] Research Program in Systems Oncology, University of Helsinki, Helsinki, Finland. ^[10]